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Currently, only two preeclampsia susceptibility genes (ACVR2A, STOX1) have been identified within confirmed regions with
significant genome-wide linkage, although many genetic screens in multiple populations have been performed. In this paper,
we focus on the STOX1 gene. The epigenetic status of this gene is discussed explaining the maternal transmission of the STOX1
susceptibility allele observed in preeclamptic families. The known upstream regulation and downstream eﬀector genes of the
transcription factor STOX1 are described. Finally, we propose a model in which we combine the cell type-specific and allele-
specific eﬀects of STOX1. This includes intrinsic eﬀects (diﬀerential CpG island methylation) and extrinsic eﬀects (regulation of
eﬀector genes).
1. Outline of This Paper
The importance of the STOX1 preeclampsia susceptibility
gene, as discovered in 2005 in Dutch females [1], was initially
challenged [2, 3]. However, the latest data including those
from independent groups not only confirm the role of
STOX1 in trophoblast dysfunction underlying preeclampsia
[4–6] but also indicate a role for its paralog, STOX2
[7]. Rather than providing a complete overview of all
aspects of preeclampsia, we provide a focused overview by
summarizing and discussing the latest data on the role of the
STOX1 as a key player in trophoblast dysfunction underlying
familial early-onset preeclampsia with growth retardation.
We propose a model in which we combine the cell type-
and allele-specific (epi)genetic eﬀects of STOX1 and suggest
future directions of research.
2. Introduction
Preeclampsia is a pregnancy-associated disease occurring in
5–8% of pregnancies and a major cause of maternal and
fetal morbidity and mortality. The disease is characterized
by maternal symptoms which may occur from 20 weeks
gestation onwards, and which consist of de novo hyperten-
sion (diastolic blood pressure >90mmHg with increment
>20mmHg from first trimester diastolic blood pressure)
and proteinuria (>300mg per 24 h) as defined by the Royal
College of Obstetricians and Gynaecologists [8]. Although
the symptoms occur in the mother, it is now well established
that the placenta is the driving force; the only cure currently
available is delivery of the baby and thus removal of the
placenta [9].
In first trimester placenta, insuﬃcient spiral artery
remodeling is the fetal pathophysiological origin of
preeclampsia [10]. In a normal pregnancy, extravillous
trophoblasts from the fetal placenta invade the maternal
decidua up to one-third of the myometrium (see also
Figure 1). These trophoblasts are thereby transforming
the maternal spiral arteries by replacing smooth muscle
and elastic tissue with fibrinoid material changing them
from low-capacity high-resistance into high-capacity
low-resistance vessels. In preeclampsia, this extravillous
trophoblast-directed spiral artery remodeling is incomplete
leading to a decrease in placental blood flow, which
subsequently leads to a response from the mother increasing
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Figure 1: Model of a villus with an extravillous trophoblast column invading the maternal decidua. Below this model, showing diﬀerent
cell types within and originating from a villus, a table shows the STOX1 methylation pattern observed or hypothesized to be found in the
diﬀerent cell types. YY: placenta homozygous for the Y-allele; HH: placenta homozygous for the H-allele; uu: both alleles are unmethylated;
mm: both alleles are methylated; um: imprinting (only one allele is methylated).
her blood pressure. This in turn leads to maternal
systemic failure giving rise to the maternal symptoms
[10].
3. Preeclampsia Is a Heterogeneous Disease
It is well established that preeclampsia is a multifactorial
disease in which both fetal, that is, placental and maternal,
factors are contributing [8]. Diﬀerent combinations of
factors can then lead to diﬀerences in disease severity, time
of onset, and the occurrence of additional complications,
for example, IUGR (Intra-Uterine Growth Restriction).
Some of these factors will also run in specific families
as there is also a strong genetic component found in the
occurrence of preeclampsia [11]. Although already three
pathways are known to be involved in preeclampsia, that
is, PlGF-sFLT-sENG, TGFβ-NOS, and COMT-2ME [9, 12],
these are all second-order factors that give rise to the
maternal symptoms. The first-order causative factors, both
placental and maternal, are still largely unknown. One
of the important starting points in the identification of
these first-order factors is to subcategorize the disease to
yield phenotypic homogenous patient populations. The
Dutch patients associated with STOX1 turned out to be
phenotypically homogenous as defined by familial early-
onset preeclampsia with an abnormal placental development
complicated by IUGR [13, 14].
4. Preeclampsia Susceptibility Genes Reside in
Chromosomal Regions with Demonstrated
Genome-Wide Linkage
To identify factors involved in preeclampsia, multiple genetic
screens (genome-wide scans, variance-components linkage
analysis, and association analysis) have been performed in
multiple patient populations (families, case control) [13–
20]. This has yielded limited results; only two susceptibility
genes have emerged, namely, ACVR2A [21] and STOX1 [1],
both within confirmed regions with significant genome-wide
linkage and both involving normal variations (SNPs) in line
with the common variant-common disease hypothesis [22].
Both of these genes were originally identified in familial
forms of preeclampsia. Additional susceptibility genes and
alleles of the same type as found in ACVR2A and STOX1
(common polymorphisms) can also be identified by power-
ful approaches using genome-wide case-control association
analyses. One example, the data are not in the public domain
yet, is the ongoing GenPE study by the Wellcome Trust Case
Control Consortium (WTCCC2, 2000 cases, 2500 controls)
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complemented with data from WTCCC3 (2225 cases, 2500
controls) (http://www.wtccc.org.uk). By design, most cases
are from nonfamilial forms; the outcome of these case-
control studies is therefore bound to be diﬀerent from, but
complementary to, the family-based linkage studies. These
studies will predominantly identify maternal susceptibility
alleles associated with low to moderate risks and high
population frequencies and associated with a low familial
component and with the less fatal forms (late-onset without
growth retardation). Placental susceptibility alleles with high
risks, low population frequencies, and representing the
strongly fatal forms (early-onset with growth retardation)
with high familial components have been and will be
identified by the linkage studies of aﬀected families.
5. Familial Preeclampsia Susceptibility Genes
As already mentioned above, only two preeclampsia sus-
ceptibility genes have been identified so far, ACVR2A [21]
and STOX1 [1]. ACVR2A, located on 2q22, was originally
identified in an Australian/New Zealand population of
preeclamptic pedigrees [21, 23]. Also, in a Norwegian case-
control study, SNPs (Single Nucleotide Polymorphisms)
within this gene were found to give significant linkage [24].
ACVR2A is a receptor for the cell-signaling protein Activin
A. Activin A has a major role in promoting decidualization
of endometrial stromal cells [25] and in the regulation of
trophoblast diﬀerentiation and invasion into the decidua
[26]. Secondly, multiple studies have found increased Activin
A in serum of preeclamptic women [27], making its receptor
ACVR2A a very interesting protein in the development of
preeclampsia. No functional studies have yet been published
looking at the significance of the intronic SNPs of ACVR2A
found in preeclamptic patients [21, 23, 24]. Although
intronic SNPs do not appear to be relevant, they should not
be discarded as it can be envisaged that these SNPs are within
areas controllingACVR2A transcription or are locatedwithin
novel yet to be identified transcripts.
Our identification of the STOX1 gene was performed
in a Dutch population consisting of aﬀected siblings and
their relatives [13]. This identification was preceded by
microsatellite marker analysis which revealed a parent-of-
origin eﬀect; the alleles shared between aﬀected preeclampsia
sisters were always maternal in origin [14]. By sequencing the
complete coding region with linkage on chromosome 10q22,
the STOX1 Y153H common polymorphism was identified,
with maternal transmission in three generations [1]. The
preeclamptic families with linkage to 10q22 and associated
with STOX1 were a phenotypically homogenous patient
cohort suﬀering from familial severe early-onset preeclamp-
sia complicated by IUGR. This indicates that the disease
in these families has a fetal, that is, placental, origin. In
this respect, discordant monozygotic twins provide excellent
evidence for the placental origin of early-onset preeclampsia;
the consistent observation in monozygotic parous twins
lacking concordance for preeclampsia implicates that fetal,
that is, placental, contributions are essential [28]. Therefore,
the discordance seen in monozygous parous twins is in
strong favor of genetic but placental origin of preeclampsia.
The placental origin of severe early-onset preeclampsia
has an important implication in genetic screens; the fetal
genotype directs the maternal phenotype [29]. It is there-
fore essential to realize that research on genetic linkage
in familial early-onset preeclampsia should focus on the
placental genotype rather than the maternal genotype. For
case-control studies, the correction needed and/or allowed
is that preeclamptic females born from unaﬀected and
aﬀected mothers should be considered controls and cases,
respectively. The importance of the criteria mentioned above
can immediately be seen in studies that have tried to confirm
the STOX1 susceptibility allele in their population [2–4].
Firstly, the preeclamptic women were not clearly defined, the
populations consisted of a combination of mild and severe,
early- and late-onset preeclampsia, and not always with
proof of familial inherited disease. Secondly, as the studies
were performed using the maternal genotype, these patients
can only be informative if their mother had developed
preeclampsia as well. In one study, also performed in a
Dutch population, they did take both criteria into account
by performing a transmission distortion test (TDT) with
correction for grandmaternal origin, and a significant mater-
nal transmission of the STOX1 Y153H allele was detected in
preeclamptic families when looking across three generations
[4]. Recently, another study has been published looking at
the STOX1 Y153H SNP in the Norwegian population. Again
no significant transmission of the H-allele was found when
the preeclampsia patients were analyzed in total. But, when
looking at recurrent preeclampsia patients, a trend towards
significance was detected in H-allele transmission when also
corrected for the potential of a parent-of-origin eﬀect [7].
However, these data were obtained in the maternal instead
of the placental genotype, thereby diluting the true maternal
transmission as not all of these mothers were also born out of
a preeclamptic pregnancy. This study, however, also looked at
expression of diﬀerent genes in decidua from preeclampsia,
IUGR, preeclampsia complicated by IUGR, and uncom-
plicated pregnancies; no diﬀerences were found in STOX1
expression between these groups. Interestingly, a significant
diﬀerence was observed for STOX2 gene expression when
healthy decidua samples were compared to decidua samples
that suﬀered from preeclampsia complicated by IUGR, where
the preeclampsia samples showed a lower expression of
STOX2 compared to controls [7]. Although the analysis
was performed in term decidua samples which contain
mainly maternal cells, they do consist of approximately
20% placental extravillous trophoblasts. The STOX2 gene
on chromosome 4q35 is located in close proximity to a
chromosomal area (4q31-4q32) that has been implicated in
preeclampsia in diﬀerent populations (Finland, Australia,
and New Zealand) as well [19, 20, 30]. No function has
been allocated to this paralog of STOX1, but as it has a
high sequence similarity to STOX1, some of its functions
are potentially comparable. Interestingly, as a comparable
function to STOX1, which shows a gain-of-function as
discussed below, is suggested, and STOX2 is downregulated
in preeclampsia samples, compatible with a loss-of-function,
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this would indicate that these two genes have similar
functions but opposite eﬀects in placental function.
6. Epigenetics of STOX1
Although a parent-of-origin eﬀect was already noticed in
the first microsatellite analysis [14], as well as maternal
transmission of the STOX1 Y153H susceptibility allele
by sequencing the DNA of multiple generations [1], no
(diﬀerential) methylation could be detected in the CpG
island located within the promoter region of STOX1 [2, 31],
excluding the existence of imprinting of this gene controlled
by the CpG island in the promoter. Recently, however, we
identified and analyzed another CpG island located in intron
1 of STOX1 [32]. Methylation of this intronic CpG region
leads to reduced expression in common with the normal
association between hypermethylation and downregulation
of expression. Secondly, in specific cells, this region is subject
to diﬀerential and allele-specific methylation. In column
extravillous trophoblast samples, the methylated allele is
paternal in origin. No allele-specific methylation could be
detected in early placenta samples consisting of multiple cell
types, but a significant increase in methylation was seen in
samples homozygous for the STOX1 Y153H preeclampsia
susceptibility allele [32]. As column extravillous trophoblasts
are formed from villous cytotrophoblasts, we hypothesize
that these cells are paternally imprinted as well. In cell types,
where methylation is independent of parental origin, the
Y153H genotype has the potential to direct the level of
methylation [32]. How these cell type and allelic diﬀerences
can be integrated with the function of STOX1 in the placenta
will be discussed in the model proposed below.
7. STOX1 Is a Transcription Factor
Three STOX1 isoforms are known to be expressed with iso-
form A being the full-length protein. Although also isoforms
B and C contain the complete (B) or part (C) of the winged
helix DNA-binding domain, they both do not contain a
nuclear export signal (NES), only a nuclear localization
signal (NLS), keeping them confined to the nucleus and
nucleolus, respectively. The general focus therefore is on
isoformA as this is the only isoform to contain the regulatory
domains needed for its functioning as discussed below.
The STOX1 winged helix DNA-binding domain shows
great similarity to the binding domain seen in the family
of FOX transcription factors [1]. Its upstream regulation
mechanism is also similar as seen in multiple members of
the FOX transcription factor family, the PI3K-Akt pathway
[6]. When phosphorylated by Akt, the STOX1 protein
is inhibited from entering the nucleus and subsequently
degraded by ubiquitination. When phosphorylation does
not take place, STOX1 functions as a transcription factor
in the nucleus with binding to DNA. The Y153H SNP
is located within the winged helix binding domain and
aﬀects an amino acid with high molecular eﬀect [1]. By
chromatin immunoprecipitation assays, it was established
that in the extravillous trophoblast cell line SGHPL-5, the
H-allele gives a higher binding aﬃnity as does the Y-allele
in one of the STOX1 downstream eﬀector genes, CTNNA3
[6]. The CTNNA3 gene was one of the original candidate
eﬀector genes based on its chromosomal location in close
proximity to STOX1, its function in cell-cell adhesion, and
its upregulation found in a preliminary microarray analysis
done in STOX1-transfected SGHPL-5 cells, an extravillous
trophoblast cell line. By studying both SGHPL-5 cells and
villous explants, we showed that by binding of STOX1 to
the CTNNA3 promoter this increased the expression of αT-
catenin, the protein product of CTNNA3, and component
of the cell-cell adhesion complex. This in turn leads to
reduced trophoblast invasion and maintains proliferation
[6]. Furthermore, villous explants homozygous for the
STOX1 H-allele associated with preeclampsia have a reduced
trophoblast outgrowth and an induced responsiveness of
CTNNA3 expression upon STOX1 expression [6]. In other
words, the genotype linked to preeclampsia, that is, STOX1
Y153H, has a demonstrated eﬀect on extravillous trophoblast
invasion, central in the etiology of preeclampsia.
The intraintronic gene of CTNNA3, LRRTM3, is also
an eﬀector gene of STOX1 [33]. Although LRRTM3 is
also expressed in placenta, most studies performed on its
function are done in brain tissue and cells. This interest
comes from the finding that LRRTM3 promotes APP
(Amyloid Precursor Protein) processing by BACE1, leading
to an increase in Amyloid beta production [34]. Amyloid
beta is found to be accumulated in brains of Alzheimer’s
disease patients. STOX1 was found to be able to transactivate
LRRTM3 in brain and placenta and showed upregulated
expression in brains aﬀected by Alzheimer’s disease [33].
A successful genome-wide approach to identify STOX1
target genes has been described by Rigourd and cowork-
ers [5]. By stable transfection of STOX1 in the JEG-3
choriocarcinoma cell line as a model for trophoblasts, they
identified and confirmed by quantitative RT-PCR five genes
upregulated (PTGDS, ALOX5, TNFSF10, beta-ARRESTIN,
and TMEM45a), while four genes were found to be down-
regulated upon STOX1 overexpression (ANXA3, ZNF22,
APOA2, and FAM43A) [5]. Furthermore, by analyzing
the promoter regions of genes aﬀected by STOX1 in the
microarray analysis, the most significant promoter binding
site being located more than once in each promoter was
found to be the FOX transcription factor binding site FKHD.
As the STOX1 DNA-binding domain shows great similarity
to FOX transcription factors, promoters containing multiple
FKHD sites were chosen for chromatin immunoprecipitation
experiments followed by quantitative PCR. Promoter regions
of six genes (COL6A3, S100A4, ARRDC3, TNFSF10, EBI3,
and PLCB1) were found to be significantly enriched in cells
overexpressing STOX1 [5]. The microarray data of this study
were also compared to published transcriptomic data com-
paring normal and preeclamptic placentas. The correlation
between these studies was found to be highly significant
looking at genes aﬀected by STOX1- and preeclampsia-
modified genes [5]. Interestingly, the microarray data by
Rigourd and coworkers has subsequently been used in the
study identifying downregulation of STOX2 in preeclamptic
deciduas complicated by IUGR. Their data also found
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significant correlation between the genes that were up- or
downregulated in JEG-3 cells overexpressing STOX1 and
the decidua samples of preeclamptic women [7]. Therefore,
although JEG-3 cells were used with STOX1 overexpression
to induce eﬀects, the outcomes are comparable to physio-
logical changes found in preeclampsia samples, justifying the
microarray results obtained.
8. An Integrated Model of STOX1 in
Placental Cells
It has become clear that processes in the early placenta
in which STOX1 is involved are cell type dependent and
allele dependent. This includes intrinsic eﬀects (diﬀerential
CpG island methylation) and extrinsic eﬀects (regulation
of eﬀector genes) [6, 32]. The cell type-specific eﬀects on
expression observed can be combined with the methylation
pattern seen in a model depicted in Figure 1. The model
shows the methylation status of the diﬀerent cell types
within the early placenta in combination with the Y153H
allele carried. For simplicity, only the homozygous alleles are
shown. It can be seen that, within the villus, stromal cells and
syncytiotrophoblasts are not subject to imprinting, but can
be either methylated or unmethylated [32]. However, their
methylation status is dependent on the Y153H allele carried,
with the placentas homozygous for the H-allele showing a
higher level of methylation than the placentas homozygous
for the Y-allele [32]. Although syncytiotrophoblasts in our
model are not subject to imprinting, this cannot be ruled
out as syncytiotrophoblasts, like extravillous trophoblasts,
are originating from villous cytotrophoblasts. The villous
cytotrophoblasts are hypothesized to be imprinted within
the villus, but as this is only a small population of cells it
does not change the overall methylation status observed in
early placenta samples. The proliferative column extravillous
trophoblasts are proven to be paternally imprinted, but as
methylation is less than 50% [32] diﬀerentiation of the
proliferative extravillous trophoblasts into invasive extrav-
illous trophoblasts is hypothesized to be subject to loss of
imprinting. Early placenta column extravillous trophoblasts
homozygous for the H-allele show a higher binding aﬃnity
to the CTNNA3 eﬀector gene than placentas homozygous
for the Y-allele [6]. This is followed by a trend towards
higher expression of CTNNA3 mRNA in these cells. This
is in agreement with the proposed model as these cells are
not subject to diﬀerences in methylation level caused by
parental independent H-allele directed methylation. This is
not the case in the villus part of the early placenta. Although
placentas homozygous for the H-allele still will have a higher
binding aﬃnity, this is not translated in an upregulated
expression of CTNNA3; there is even a trend towards
downregulated expression in these placentas [6]. This eﬀect
can be explained using the model; a vast amount of cells
within the villus have a methylation status that is dependent
on the allele carried, giving placentas homozygous for the
H-allele an overall downregulated expression caused by
the higher level of methylation. Furthermore, of interest
is the observation that CTNNA3 itself is also subject to
paternal imprinting in villous cytotrophoblasts [35]. Upon
diﬀerentiation into proliferative extravillous trophoblasts
the expression of CTNNA3 becomes biallelic and is absent
after further diﬀerentiation into invasive extravillous tro-
phoblasts.
9. Conclusions and Future Directions
This paper has been intended to provide an overview of
the data available from successful genetic screens to identify
preeclampsia susceptibility genes and subsequent studies
on these genes, that is, ACVR2A and STOX1, in other
populations. These two genes are a first step on defining
preeclampsia; diﬀerent genes aﬀect diﬀerent pathways con-
verging to a final common endophenotype: hypertension
with proteinuria. As most data available is on the transcrip-
tion factor STOX1, it has been the main focus of this paper
to discuss the epigenetic status of STOX1, to explain the
maternal transmission seen in preeclamptic families, and
its upstream regulation and downstream eﬀector genes in
placenta and brain. Finally, we propose an integrated model
of the cell type-specific and allele-specific eﬀects on both
diﬀerential methylation as the expression of eﬀector genes of
STOX1.
STOX1, however, is only one of the genes that give
susceptibility for preeclampsia. It is therefore needed that
more genes are identified in other populations to have a
complete understanding of the origin of the disease. For new
identifications to be successful, it is essential to subcategorize
the disease to yield phenotypic homogenous patient popula-
tions and to bear in mind that for preeclampsia originating
in the early placenta it is the genotype of the children born
from these pregnancies that provide information. Secondly,
as STOX1 is a transcription factor, there are many more
genes regulated by STOX1 which need to be identified
in a genome-wide manner either by microarrays or by
chromatin immunoprecipitation experiments followed by
deep sequencing. This will provide a complete overview of
STOX1 function in placenta, brain, and other organs, in both
health and disease. Finally, by identifying which other genes
are involved in preeclampsia, especially the early-onset form
with growth retardation, a complete genotype-phenotype
correlation can be envisaged. For this to succeed, functional
studies on genes associated with preeclampsia should not
only focus on one gene but combine data that is and becomes
available. In this respect, it is very interesting to investigate
the combined action of the two genes discussed in this paper,
STOX1 and ACVR2A, using a physiological ex vivo placental
explant model which takes into account the diﬀerent cell
types involved [36]. In the end, this will provide a complete
functional interaction map of all genes involved in the origin
of preeclampsia.
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